Figure 1
Figure 1. Analysis of the C9-deficient patient with PNH. (A) Clinical profile of the C9-deficient patient with PNH. ND indicates not determined; and PNH erythrocytes, negative for both CD55 and CD59. (B) Correlation between LDH levels and PNH type III erythrocytes (%). ○, 14 patients with PNH; •, C9-deficient patient with PNH; dashed line, upper limit of normal LDH range. (C) C3d expression on erythrocytes of PNH patients with C9 deficiency (C9− PNH), with eculizumab (Ecu+ PNH), without eculizumab (Ecu− PNH), and of a patient with autoimmune hemolytic anemia (AIHA). Numbers indicate the population (%) of cells in each quadrant. (D) Arrow indicates a PIGA mutation, deletion of G (352), in the granulocyte genome exon 2 of C9− PNH. (E) Arrows indicate urine hemosiderin stained with Prussian blue of C9− PNH.

Analysis of the C9-deficient patient with PNH. (A) Clinical profile of the C9-deficient patient with PNH. ND indicates not determined; and PNH erythrocytes, negative for both CD55 and CD59. (B) Correlation between LDH levels and PNH type III erythrocytes (%). ○, 14 patients with PNH; •, C9-deficient patient with PNH; dashed line, upper limit of normal LDH range. (C) C3d expression on erythrocytes of PNH patients with C9 deficiency (C9 PNH), with eculizumab (Ecu+ PNH), without eculizumab (Ecu PNH), and of a patient with autoimmune hemolytic anemia (AIHA). Numbers indicate the population (%) of cells in each quadrant. (D) Arrow indicates a PIGA mutation, deletion of G (352), in the granulocyte genome exon 2 of C9 PNH. (E) Arrows indicate urine hemosiderin stained with Prussian blue of C9 PNH.

Close Modal

or Create an Account

Close Modal
Close Modal